A Phase 1 Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

Trial Profile

A Phase 1 Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Otlertuzumab (Primary) ; Bendamustine; Rituximab
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Emergent BioSolutions
  • Most Recent Events

    • 01 Aug 2013 The phase II portion of this trial was not conducted, according to the ClinicalTrials.gov record.
    • 13 Nov 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 05 Nov 2012 Twelve patients were enrolled and treated in the phase Ib component of the trial according to an Emergent BioSolutions media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top